Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Benebellum is a cosmeceutical skincare line developed by Skin Tech Pharma Group, specifically formulated to address hyperpigmentation, photoaging, and the damaging effects of blue light exposure. The product range includes topical formulations such as serums, foams, and creams that incorporate active ingredients like tranexamic acid and 4-hexylresorcinol. These molecules work synergistically to inhibit melanin synthesis at multiple stages of the melanogenesis pathway. Indicated for skin rejuvenation and repair, the Benebellum line aims to reduce dark spots, improve skin tone uniformity, and enhance overall radiance while providing protective benefits against environmental stressors. Although it contains biologically active molecules, it is categorized as a cosmeceutical/aesthetic medicine product rather than a traditional pharmaceutical drug.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Benebellum.